US Patent

US11571402 — Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof

Formulation · Assigned to SpringWorks Therapeutics Inc · Expires 2041-02-17 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects dispersible pharmaceutical compositions containing N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide.

USPTO Abstract

The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

Drugs covered by this patent

Patent Metadata

Patent number
US11571402
Jurisdiction
US
Classification
Formulation
Expires
2041-02-17
Drug substance claim
No
Drug product claim
Yes
Assignee
SpringWorks Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.